Biomedical Engineering Reference
In-Depth Information
[56] Mohr L, Yeung A, Aloman C, Wittrup D, Wands JR. Antibody-directed therapy for
human hepatocellular carcinoma. Gastroenterology 2004;127:S225-31.
[57] Lemarchand P, Jaffe HA, Danel C, Cid MC, Kleinman HK, Stratford-Perricaudet LD,
et al. Adenovirus-mediated transfer of a recombinant human alpha.1-antitrypsin cDNA to
human endothelial cells. Proc Natl Acad Sci U.S.A. 1992;89:6482-6.
[58] Roy Chowdhury N, Kadakol A, Sappal BS, Thummala NR, Ghosh SS, Lee SW, et al.
Gene therapy for inherited hyperbilirubinemias. J Perinatol 2001;21:S114-8.
[59] Guha C, Deb NJ, Sappal BS, Ghosh SS, Roy Chowdhury N, Roy Chowdhury J.
Amplification of engrafted hepatocytes by preparative manipulation of the host liver.
Artif Organs 2001;25:522-8.
[60] Thummala NR, Ghosh SS, Lee SW, Horwitz MS, Reddy B, Davidson A, et al. A non-
immunogenic adenoviral vector, coexpressing CTLA4Ig and bilirubin-uridine-diphospho-
glucuronateglucuronosyltransferase permits long-term, repeatable transgene expression in
the Gunn rat model of Crigler-Najjar syndrome. Gene Ther 2002;9:981-90.
[61] Shinohara ET, Lu B, Hallahan DE. The use of gene therapy in cancer research and treat-
ment Technol. Cancer Res Treat 2004;3:479-90.
[62] Springer CJ, Niculescu-Duvaz I. Prodrug-activating systems in suicide gene therapy.
J Clin Invest 2000;105:1161-7.
[63] Brand K, Loser P, Arnold W, Bartels T, Strauss M. Tumor cell-specific transgene
expression prevents liver toxicity of the adeno-HSVtk/GCV approach. Gene Ther
1998;5:1363-71.
[64] Sterman DH, Treat J, Litzky LA, Amin KM, Coonrod L, Molnar-Kimber K, et al.
Adenovirus-mediated herpes simplex virus thymidine kinase/ganciclovir gene therapy in
patients with localized malignancy: results of a phase I clinical trial in malignant meso-
thelioma. Hum Gene Ther 1998;9:1083-92.
[65] Herman JR, Adler HL, Aguilar-Cordova E, Rojas-Martinez A, Woo S, Timme TL, et al.
In situ gene therapy for adenocarcinoma of the prostate: a phase I clinical trial. Hum
Gene Ther 1999;10:1239-49.
[66] May P, May E. Twenty years of p53 research: structural and functional aspects of the p53
protein (published erratum appears in Oncogene). Oncogene 1999;18:7621-36.
[67] Clayman GL, el-Naggar AK, Lippman SM, Henderson YC, Frederick M, Merritt JA,
et al. Adenovirus-mediated p53 gene transfer in patients with advanced recurrent head
and neck squamous cell carcinoma. J Clin Oncol 1998;16:2221-32.
[68] Schuler M, Rochlitz C, Horowitz JA, Schlegel J, Perruchoud AP, Kommoss F, et al.
A phase I study of adenovirus-mediated wild-type p53 gene transfer in patients with
advanced non-small cell lung cancer. Hum Gene Ther 1998;9:2075-82.
[69] Swisher SG, Roth JA, Nemunaitis J, Lawrence DD, Kemp BL, Carrasco CH, et al.
Adenovirus-mediated p53 gene transfer in advanced non-small-cell lung cancer. J Natl
Cancer Inst 1999;91:763-71.
[70] Tsao YP, Huang SJ, Chang JL, Hsieh J, Pong RC, Chen SL. Adenovirus-mediated p21
(WAF1/SDII/CIP1) gene transfer induces apoptosis of human cervical cancer cell lines. J
Virol 1999;73:4983-90.
[71] Schreiber M, Muller WJ, Singh G, Graham FL. Comparison of the effectiveness of ade-
novirus vectors expressing cyclin kinase inhibitors p16INK4A, p18INK4C, p19INK4D,
p21 (WAF1/CIP1) and p27KIP1 in inducing cell cycle arrest, apoptosis and inhibition of
tumorigenicity. Oncogene 1999;18:1663-76.
[72] Kobayashi S, Shirasawa H, Sashiyama H, Kawahira H, Kaneko K, Asano T, et al.
P16INK4a expression adenovirus vector to suppress pancreas cancer cell proliferation.
Clin Cancer Res 1999;5:4182-5.
Search WWH ::




Custom Search